WuXi AppTec Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $19.88
50-Day Range
MA: $17.58
52-Week Range
Now: $19.88
Average Volume1,125 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
WuXi AppTec Co., Ltd. provides research and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through, China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CMO/CDMO Services, and Other segments. It offers pharmaceutical discovery services across the drug discovery process; laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CMO/CDMO services; and administrative services, as well as sells scrap materials. The company was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Industry, Sector and Symbol

Industry Diagnostics & Research
Phone86 21 5046 1111
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


WuXi AppTec Reports Strong 2020 Annual Results
March 30, 2021 |  finance.yahoo.com
WuXi AppTec A earnings preview: what Wall Street is expecting
March 29, 2021 |  markets.businessinsider.com
WuXi Apptec completes $135M purchase of Oxgene
March 2, 2021 |  bizjournals.com
News for WuXi AppTec Co., Ltd. Registered Shs -H- Unitary Reg S-144A
December 24, 2020 |  markets.businessinsider.com
See More Headlines


Overall MarketRank

1.00 out of 5 stars

Medical Sector

1054th out of 2,024 stocks

Diagnostics & Research Industry

4th out of 15 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WUXIF News and Ratings via Email

Sign-up to receive the latest news and ratings for WUXIF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

WuXi AppTec (OTCMKTS:WUXIF) Frequently Asked Questions

Is WuXi AppTec a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for WuXi AppTec in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" WuXi AppTec stock.
View analyst ratings for WuXi AppTec
or view top-rated stocks.

What stocks does MarketBeat like better than WuXi AppTec?

Wall Street analysts have given WuXi AppTec a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but WuXi AppTec wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting WuXi AppTec?

WuXi AppTec saw a drop in short interest in March. As of March 31st, there was short interest totaling 71,100 shares, a drop of 95.0% from the March 15th total of 1,408,500 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 711.0 days.
View WuXi AppTec's Short Interest

Who are WuXi AppTec's key executives?

WuXi AppTec's management team includes the following people:
  • Dr. Ge Li, Co-Founder, Chairman, Pres & CEO (Age 54)
  • Dr. Qing Yang Ph.D., Co-CEO & Exec. Director (Age 52)
  • Dr. Edward Hu, Vice Chairman & Global Chief Investment Officer (Age 58)
  • Mr. Bih-Hsin Chu, Sr. VP & CFO (Age 50)
  • Mr. Peter Tong, Sr. VP & COO
  • Dr. Shuhui Chen, Exec. VP, Chief Scientific Officer & Head of DDSU (Age 57)
  • Mr. Tianyi Zhang, IR Director
  • Mr. Yao Chi, Board Sec. & Exec. Director of the Corp. Legal Office (Age 38)
  • Dr. Ning Zhao, Global Head of HR, Sr. VP & Exec. Director (Age 54)
  • Mr. Zhaohui Zhang, Sr. VP, Head of Gov. Affairs & Policy Research and Exec. Director (Age 51)

Who are some of WuXi AppTec's key competitors?

What is WuXi AppTec's stock symbol?

WuXi AppTec trades on the OTCMKTS under the ticker symbol "WUXIF."

How do I buy shares of WuXi AppTec?

Shares of WUXIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is WuXi AppTec's stock price today?

One share of WUXIF stock can currently be purchased for approximately $19.88.

How many employees does WuXi AppTec have?

WuXi AppTec employs 25,743 workers across the globe.

What is WuXi AppTec's official website?

The official website for WuXi AppTec is www.wuxiapptec.com.

How can I contact WuXi AppTec?

The company can be reached via phone at 86 21 5046 1111.

This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.